Details for Patent: 7,608,616
✉ Email this page to a colleague
Which drugs does patent 7,608,616 protect, and when does it expire?
Patent 7,608,616 protects DORAL and is included in one NDA.
Summary for Patent: 7,608,616
| Title: | Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia |
| Abstract: | Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination. |
| Inventor(s): | Cartt; Steve (Union City, CA) |
| Assignee: | Questcor Pharmaceuticals, Inc. (Union City, CA) |
| Application Number: | 12/132,575 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,608,616
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galt Pharms | DORAL | quazepam | TABLET;ORAL | 018708-003 | Feb 26, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION | ⤷ Sign Up | ||||
| Galt Pharms | DORAL | quazepam | TABLET;ORAL | 018708-001 | Dec 27, 1985 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
